{"id":989117,"date":"2026-08-04T07:28:28","date_gmt":"2026-08-04T11:28:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/"},"modified":"2026-08-04T07:28:28","modified_gmt":"2026-08-04T11:28:28","slug":"ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/","title":{"rendered":"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Aug.  04, 2026  (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6q_4HtCKnXKEgEw3bnLo5eiVY0gnKtc1HPZK6KmaLzE0SoQ3j6u74_STRKOkys6gDQtR60cIUFREee3eqPu7xarwtOByHquTm_54tQCzLh1gKZzpBvKaauOzhbkyBilK\" rel=\"nofollow\" target=\"_blank\">Molly Carr<\/a>, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company\u2019s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.\u00a0\u00a0<\/p>\n<p align=\"justify\">Prior to joining iBio, Dr. Carr held senior clinical development, medical affairs, business development and academic positions at leading biopharmaceutical companies and institutions, including Eli Lilly and Company, GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University and the University of Washington. Most recently, she served as Clinical Head and Associate Vice President of Lilly\u2019s Insulin and Glucagon Franchise, where she oversaw the company\u2019s insulin portfolio and clinical development team, including the Phase 3 program for efsitora, a once-weekly insulin, as well as programs spanning prandial insulin, nasal glucagon, biosimilars and legacy insulins. Dr. Carr earned her M.D. from Columbia University College of Physicians and Surgeons and completed her residency and fellowship in endocrinology at the University of Washington.<\/p>\n<p align=\"justify\">\u201cAdding Molly to our leadership team is a critical step as we advance our obesity and cardiometabolic pipeline into the clinic,\u201d said Martin Brenner, D.V.M., Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. \u201cHer rare combination of deep scientific expertise in endocrinology and metabolic disease, together with hands-on experience leading clinical programs across all stages of development, will be invaluable as we advance IBIO-600 and IBIO-610 into their next clinical phases. Her appointment reflects iBio\u2019s growth into a clinical-stage company and strengthens our ability to execute on our programs with the rigor and focus required to bring them closer to patients.\u201d<\/p>\n<p align=\"justify\">\u201cThe science behind iBio&#8217;s clinical candidates is closely aligned with my experience in endocrinology, obesity, muscle biology and cardiometabolic disease, and I believe these programs have the potential to meaningfully improve body composition and overall quality of life for patients,&#8221; added Dr. Carr. &#8220;I was also drawn to iBio\u2019s clear clinical vision, highly collaborative culture, and commitment to translating differentiated science into new medicines. I look forward to working with this world-class research team to advance these candidates through the clinic.\u201d<\/p>\n<p align=\"justify\">iBio also today announced that the company has granted Dr. Carr options to purchase 430,000 shares of its common stock as inducement awards outside the company\u2019s 2023 Omnibus Incentive Plan. The grant was approved by the Compensation Committee and made as a material inducement to Dr. Carr\u2019s employment in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">The option award has an exercise price of $1.40 per share, equal to the closing price of the company\u2019s common stock on July 31, 2026, the grant date, and a ten-year term. The option will vest 25% on the one-year anniversary of the grant date, with an additional 6.25% vesting every three months thereafter, provided Dr. Carr remains employed by the company through each applicable vesting date. These inducement awards also provide for accelerated vesting in connection with a change in control of the company or certain involuntary terminations of Dr. Carr\u2019s employment.<\/p>\n<p>\n        <strong>About iBio, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>iBio <\/strong>(Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio\u2019s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VGv-Gm6A4l5h84UMAyCSKdh9zUURuUPpNFHxr2RmzupHX0NFsXkgHkGFlxxLGBLeWvD3E_1N3OZhEGHFkELZQUP8jlfhvWbNs8lfi_-Hvw1GOHEgDSI4CDIekPn4v81gk9v-T8z9jZ17voOgdUn9byD4QPsxByD9pkpVvOdcxM1m3QxNoBTA5T4N8qAmSDmk3H-kzHocewSd2K6p7QIXHGbPD2loT3bn8Vk1dAcJQCj9NMmaCEt-EuHC9LNWbV3dAP6cSiSE50G9qEwZ7M3Xqg==\" rel=\"nofollow\" target=\"_blank\">www.ibioinc.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nJINS7RhvXaawrOjtOkN2fxyv3mOAr3qu1Nq57vVNPkYvjD6cEXHcVp6MMu0uoSqhIMtC5u7xXLhaHk9osXKEqDGOrR40Ls5CxTEh3FkLCSIv1sdwDUmvYcqzv0S4YwFH0r7eDaIclYFsjjO7nBnBO4XwijkmSZSDHlWWEHIdo2zuPXQSaiqTd_e91O7Po7TTKKJ3eja-JoDC9K-bLt6sXIFxUJNx_o8Myt0SIpVI9X6CtGBERxLTfvU6n_7r39XjTsVQhkqtOpDKz42ns3rF3m3av2YALhfq0ESFkKZmvzrcdIGWCJdpsSVbj-AtiOZtRIR_H0iV7aOqPkTnlqT5Z6MX9W8LU21pH7Duh2wCy-cQrK843QEse9SaRP721LNfu6B2277tlvy8yKLikrOVdWgm3dxqwDLNtnSJfJP-37BmT-7etB0zehu1qliZrcrP18sk4z5H5G5SV1HJlgoAYPsACZXPyu07LC_t2bUdleO5jKZCfw1Hqf6_1TsV2o9IPBUCp6VaEzIB8YnGvB-OT_sYw4kkiIqGQ3kKL5GeJN2Q2LX2Mw1liizLNsnUwfliq-5ksUNFfaLzTx4t2BJ5a5L6eFJaG0k5KPYn5dy2_ZfiG7jhQmvAqOfjrdxtxDTckDzu-R4CFs2_P22cEH8fRTCxIzNiRqHOfkdVBTfUN8bK-wNZoTJ5irwNYABBcdQ9uoexFwk79b3SW0rzYIf729kgGrND3p6Y4J0spCB3-F2dS81UCRSK_6vxGjj0tjX\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. Words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;intend&#8221; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding Dr. Carr leading the company\u2019s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development; the company advancing its obesity and cardiometabolic pipeline into the clinic; Dr. Carr\u2019s expertise and hands-on experience leading clinical programs across all stages of development being invaluable to the company as it advances IBIO-600 and IBIO-610 into their next clinical phases; Dr. Carr\u2019s appointment reflecting iBio\u2019s growth into a clinical-stage company and strengthening the company\u2019s ability to execute on its programs with the rigor and focus required to bring them closer to patients; Dr. Carr\u2019s belief that these programs have the potential to meaningfully improve body composition and overall quality of life for patients; iBio\u2019s commitment to translating differentiated science into new medicines; the vesting of the option granted to Dr. Carr; and the accelerated vesting of the inducement award in the event of termination in connection with a change in control of the company or certain involuntary terminations of Dr. Carr\u2019s employment. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the contributions to be made by Dr. Carr; iBio\u2019s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio\u2019s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio\u2019s product candidates in the marketplace and the successful development, marketing or sale of products; whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio\u2019s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>iBio, Inc.<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-emiwIPInqdFWKixsxB_AbCO6MK2qviKiuU2kI15zykNltu-6ra3gGhoni4g0prXGl4i2tZqRh31fmNnF8aGWRrlwXNb_HVFkgRhAZcPL39__4p8vETP-WN9Kg7h1J98fycy8jqNCMW4C_7lyr57yk2jazwrmS81ftiz3Pk_ANuX6HtJLfKBnFsG8uRnfYOeQqGPRcv_C-nXRCbPYynDajTTANMAcKW85B08bYDCMQY=\" rel=\"nofollow\" target=\"_blank\">ir@ibioinc.com<\/a><\/p>\n<p>\n        <strong>Media Contacts:<\/strong><br \/>\n        <br \/>Ignacio Guerrero-Ros, Ph.D., or David Schull<br \/>Russo Partners, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fkaQecpZFlbu7CP29CdnlIWttPNk3TS4qD4-__cNnzO-o7HvOFl9JOmj_Ht_1lCaHFVYne7eozR1gQXsnZ-MDYPM4c8Vc-ts3A-keayiOgceSfivm__BHgpxhjt47nOIldMwFSqPpGjyNuj51ni6ooEbre9_gX5NjiY3rcIPYb4=\" rel=\"nofollow\" target=\"_blank\">Ignacio.guerrero-ros@russopartnersllc.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RhtwWUrcOXhM_als_x3PI7KtXxudc51RVx6PR1kWquBhImVP56WUQ7Xw8WatQIKs8cTqxbsVq1lBGwP1CnCyXiweHB9BvOyro-dmsi4j0KoHUhwjUkykHhW0GUaDNwNZQkVP2dO-84q86Huqqa9HmA==\" rel=\"nofollow\" target=\"_blank\">David.schull@russopartnersllc.com<\/a><br \/>(858) 717-2310 or (646) 942-5604<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODM2MmUwZjAtZTNhNi00ZmY0LWJlNzQtNDY0YTI5YmE2NjgwLTEwOTkxNDQtMjAyNi0wOC0wNC1lbg==\/tiny\/iBio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company\u2019s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.\u00a0\u00a0 Prior to joining iBio, Dr. Carr held senior clinical development, medical affairs, business development and academic positions at leading biopharmaceutical companies and institutions, including Eli Lilly and Company, GlaxoSmithKline, CSL &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-989117","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company\u2019s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.\u00a0\u00a0 Prior to joining iBio, Dr. Carr held senior clinical development, medical affairs, business development and academic positions at leading biopharmaceutical companies and institutions, including Eli Lilly and Company, GlaxoSmithKline, CSL &hellip; Continue reading &quot;iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-04T11:28:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer\",\"datePublished\":\"2026-08-04T11:28:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/\"},\"wordCount\":1145,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/\",\"name\":\"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=\",\"datePublished\":\"2026-08-04T11:28:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Market Newsdesk","og_description":"SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company\u2019s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.\u00a0\u00a0 Prior to joining iBio, Dr. Carr held senior clinical development, medical affairs, business development and academic positions at leading biopharmaceutical companies and institutions, including Eli Lilly and Company, GlaxoSmithKline, CSL &hellip; Continue reading \"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-04T11:28:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer","datePublished":"2026-08-04T11:28:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/"},"wordCount":1145,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/","name":"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=","datePublished":"2026-08-04T11:28:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjkwNiM3NzU2NTc4IzIwODc1NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-carr-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/989117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=989117"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/989117\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=989117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=989117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=989117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}